Tardive Dyskinesia Video Perspectives

Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Sage, Supernus, Tolmar and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, PsiloSterics and Quantic.

May 25, 2023

2 min watch

Save

VIDEO: Unmet needs for patients with tardive dyskinesia

Transcript

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify iwaters@healio.com if there are concerns regarding accuracy of the transcription.

There are multiple unmet needs for patients with tardive dyskinesia. First of all, trying to minimize the risk by identifying risk factors, using treatments that have lower risk of tardive dyskinesia, using doses that are not too high and don't lead to the extra pyramidal side effects.

The second need is to identify it when it's there. So, that can be helped by identifying this with patients, that this is a potential side effect. Also, with caregivers and care partners, because sometimes patients are not even aware that they have these movements, and that needs to be pointed out by people around them. And we need to assess patients, that's their need, so that we can identify tardive dyskinesia early and treat it.

And then other unmet needs are what about the psychosocial and biological consequences?

In tardive dyskinesia, topography matters. Location, location, location. So, if it's in the speech, in the tongue area, if you have a job and need to use speech and language, that can be really problematic. There can be temporomandibular joint pains, swallowing difficulties – that needs to be identified and released.

Also, if patients that have weight bearing exercise or weight bearing work and they have problems with stability because of tardive dyskinesia and the truncal area, that can be problematic.

But there can also be problems with mood and affect. People can be upset by this. They can also have secondary withdrawal and social isolation in where either patients with schizophrenia have more secondary negative symptoms because they feel ostracized and feel identified by others as being weird. So, social interactions can actually be impaired. And that is another need that we help patients to come to terms with this and also ideally have less of these symptoms, so that they can re-engage in social, vocational, educational, physical, and also psychological activities that are helpful to them.